Study Title
T2020-006: A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Protocol ID
T2020-006
Condition/s
Acute lymphoblastic leukemia
Acute myeloid leukemia
Myelodysplastic syndrome
Mixed phenotype acute leukemia
Acute undifferentiated leukemia
Blastic plasmacytoid dendritic cell neoplasm
Hodgkin lymphoma
Non-Hodgkin lymphoma
Acute myeloid leukemia
Myelodysplastic syndrome
Mixed phenotype acute leukemia
Acute undifferentiated leukemia
Blastic plasmacytoid dendritic cell neoplasm
Hodgkin lymphoma
Non-Hodgkin lymphoma
Diagnosis Stage
Relapsed/refractory
Location
NSW, VIC
Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Links
Trial Status
Open
Sites
The Children's Hospital at Westmead
Royal Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1
Age Eligibility
1 Year to 21 Years
International registry ID's
NCT05476770
| Study Title | T2020-006: A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies |
|---|---|
| Protocol ID | T2020-006 |
| Disease (Sub Disease) | Acute lymphoblastic leukemia Acute myeloid leukemia Myelodysplastic syndrome Mixed phenotype acute leukemia Acute undifferentiated leukemia Blastic plasmacytoid dendritic cell neoplasm Hodgkin lymphoma Non-Hodgkin lymphoma |
| Diagnosis Stage | Relapsed/refractory |
| Location | NSW / VIC |
| Sponsor | Therapeutic Advances in Childhood Leukemia Consortium |
| Links | https://clinicaltrials.gov/study/NCT05476770 |
| Trial Status | Open |
| Trial Open Date | 11/11/2022 |
| Sites | The Children's Hospital at Westmead / Royal Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1 |
| Age Eligibility | 1 Year to 21 Years |
| International registry ID's | NCT05476770 |